dabigatran has been researched along with Cardio-embolic Stroke in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahit, MC; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Easton, JD; Granger, CB; Grauer, C; Kleine, E; Lopes, RD; Lyrer, P; Meyerhoff, J; Sacco, RL; Segura, T; Wachter, R | 1 |
| Babálová, L; Bolek, T; Dluhá, J; Hajaš, G; Kubisz, P; Kurča, E; Mokáň, M; Nosáľ, V; Petrovičová, A; Samoš, M; Sivák, Š; Škorňová, I; Stančiaková, L; Staško, J | 1 |
| Honmou, O; Kataoka-Sasaki, Y; Kiyose, R; Magota, H; Nakazaki, M; Oka, S; Onodera, R; Sasaki, M; Ukai, R | 1 |
| Bladin, CF; Brueckmann, M; Chutinet, A; Cronin, L; Del Brutto, VJ; Diener, HC; Easton, JD; Estol, CJ; Granger, CB; Grauer, C; Kleine, E; Lyrer, P; Molina, CA; Sacco, RL; Schellinger, PD; Toyoda, K | 1 |
| Brueckmann, M; Cronin, L; Diener, HC; Grauer, C; Hagihara, Y; Kamiyama, K; Kuwashiro, T; Mori, T; Nozaki, K; Taniguchi, A; Toyoda, K; Uchiyama, S; Urano, Y | 1 |
| Chutinet, A; Diener, HC; Easton, JD; Granger, CB; Kleine, E; Marquardt, L; Meyerhoff, J; Sacco, RL; Zini, A | 1 |
| Brueckmann, M; Easton, JD; Grauer, C; Lee, BC; Liou, CW; Taniguchi, A; Toyoda, K; Uchiyama, S; Urano, Y; Wong, LKS | 1 |
| de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD | 1 |
5 trial(s) available for dabigatran and Cardio-embolic Stroke
| Article | Year |
|---|---|
Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
Topics: Administration, Oral; Age Factors; Aged; Aspirin; Atrial Fibrillation; Body Mass Index; Dabigatran; Double-Blind Method; Embolic Stroke; Female; Humans; Hypertension; Male; Middle Aged; Models, Cardiovascular; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Recurrence; Risk Factors | 2021 |
Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial.
Topics: Aspirin; Cerebral Infarction; Dabigatran; Embolic Stroke; Humans; Intracranial Embolism; Male; Risk Factors; Stroke; Tomography, Emission-Computed, Single-Photon | 2022 |
Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source - Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
Topics: Aspirin; Dabigatran; Embolic Stroke; Humans; Japan; Secondary Prevention; Tomography, Emission-Computed, Single-Photon | 2020 |
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dabigatran; Double-Blind Method; Embolic Stroke; Embolism; Female; Foramen Ovale, Patent; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Young Adult | 2021 |
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Topics: Asia, Eastern; Asian People; Aspirin; Cohort Studies; Dabigatran; Double-Blind Method; Embolic Stroke; Follow-Up Studies; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrence; Treatment Outcome | 2021 |
3 other study(ies) available for dabigatran and Cardio-embolic Stroke
| Article | Year |
|---|---|
Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolic Stroke; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2022 |
Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
Topics: Adenosine Diphosphate; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolic Stroke; Factor Xa Inhibitors; Humans; Pilot Projects; Platelet Aggregation; Pyridones; Retrospective Studies; Rivaroxaban | 2022 |
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolic Stroke; Hemorrhage; Humans; Ischemic Stroke; Models, Economic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |